Fig. 4: Enhancing antibody titers following a single low dose of KD-382.

a Overall and serotype-specific longitudinal PET values. b Genotype-specific longitudinal PET values. PET values are presented as geometric means and 95% CI. PET values were calculated only for samples with peak fold enhancement levels ≥2.5, as determined using an ADE-negative control serum (from a DENV-naïve, DENV IgG-negative individual). Statistical significance for (a) was assessed using the non-parametric Kruskall–Wallis test, followed by pairwise comparisons of each time point from months 2 to 12 against month 1 as the reference group, using Dunn’s test. The ADE risk thresholds are depicted as shaded regions: threshold 1 (1:20–1:80²²) and threshold 2 (≤1:40²³), represented by dashed lines overlaid on a pink background. The fold enhancement cut-off at 2.5 was set based on the mean peak fold enhancement observed across all 17 DENV genotypes using the ADE-negative control serum.